Hims & Hers (NYSE: HIMS) has been on a wild journey over the past year as GLP-1s drive both big gains and big losses for the ...

Fintel reports that on January 10, 2025, Citigroup downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from Neutral ...

Hims & Hers Health (HIMS) stock gained after Citi upgraded the company, while agilon health (AGL) stock slipped after its downgrade. Read more here.

Citi downgraded Hims & Hers to Sell from Neutral with a price target of $25, up from $24. The firm thinks the market is overvaluing the ...

Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) have been given a consensus recommendation of “Hold” by the ...

Teladoc's growth and profitability challenges continue amid rising competition. Learn why TDOC stock remains under pressure ...

Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees ...

When it comes to the efficacy of a hair loss treatment, there’s nothing more telling than a before and after photo.

Companies seeking to benefit from campaign promises to cut regulations and taxes are ditching diversity and climate ...

The rise of artificial intelligence has sparked plenty of discourse concerning the potential pitfalls of the technology being harnessed for nefarious ...

Pelvic floor dysfunction — or PFD — is a term for a variety of disorders that affect the muscles in your pelvic floor. If the connective tissue or muscles in your pelvis weaken over time or get ...

The Bank of Israel set the representative shekel-dollar rate down 0.248% from Monday, at NIS 3.627/$. Information ...